Targeted disruption of luteinizing hormone/human chorionic gonadotropin receptor gene.
LH/hCG receptors were disrupted by gene targeting in embryonic stem cells. The disruption resulted in infertility in both sexes. The gonads contained no receptor mRNA or receptor protein. Serum LH levels were greatly elevated, and FSH levels were moderately elevated in both sexes; estradiol and progesterone levels decreased but were not totally suppressed in females; testosterone levels were dramatically decreased and estradiol levels moderately elevated in males. The external and internal genitalia were grossly underdeveloped in both sexes. Abnormalities included ambiguous vaginal opening, abdominal testes, micropenis, dramatically decreased weights of the gonads and reproductive tract, arrested follicular growth beyond antral stage, disarray of seminiferous tubules, diminished number and hypotrophy of Leydig cells, and spermatogenic arrest beyond the round spermatid stage. LH/hCG receptor gene disruption had no effect on FSH receptor mRNA levels in ovaries and testes, progesterone receptor (PR) levels in ovaries and androgen receptor (AR) levels in testes. However, it caused a dramatic decrease in StAR and estrogen receptor-alpha (ERalpha) mRNA levels and an increase in ERbeta mRNA levels in both ovaries and testes. Estradiol and progesterone replacement therapy in females and testosterone replacement in males, to determine whether phenotype and biochemical changes were a consequence of decreased gonadal steroid levels or due to a loss of LH signaling, revealed complete restoration of some and partial restoration of others. Nevertheless, the animals remained infertile. It is anticipated that the LH receptor knockout animals will increase our current understanding of gonadal and nongonadal actions of LH and hCG.
Lei
Z M
ZM
Division of Basic Science Research Department of Obstetrics and Gynecology University of Louisville Health Sciences Center Louisville, Kentucky 40292, USA.
Mishra
S
S
Zou
W
W
Xu
B
B
Foltz
M
M
Li
X
X
Rao
C V
CV
D000818:Animals; D004958:Estradiol / Q000097:blood / Q000627:therapeutic use; D047628:Estrogen Receptor alpha; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D018390:Gene Targeting; D005835:Genitalia / Q000254:growth & development; D006801:Humans; D007246:Infertility / Q000188:drug therapy / Q000209:etiology; D007985:Leydig Cells / Q000473:pathology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D006080:Ovarian Follicle / Q000473:pathology; D010053:Ovary / Q000737:chemistry; D010750:Phosphoproteins / Q000235:genetics; D011374:Progesterone / Q000097:blood / Q000627:therapeutic use; D012333:RNA, Messenger / Q000032:analysis; D011960:Receptors, Estrogen / Q000235:genetics; D011974:Receptors, LH / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D012671:Seminiferous Tubules / Q000473:pathology; D013091:Spermatogenesis; D013737:Testis / Q000737:chemistry; D013739:Testosterone / Q000627:therapeutic use; D000098682:Steroidogenic Acute Regulatory Protein
D047628:Estrogen Receptor alpha; D010750:Phosphoproteins; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D011974:Receptors, LH; D000098682:Steroidogenic Acute Regulatory Protein; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone